+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Type 1 Diabetes Drug Market by Insulin Type, Delivery Mode, Distribution Channel, End User, Patient Age Group - Global Forecast to 2030- Product Image
Type 1 Diabetes Drug Market by Insulin Type, Delivery Mode, Distribution Channel, End User, Patient Age Group - Global Forecast to 2030- Product Image
Sale

Type 1 Diabetes Drug Market by Insulin Type, Delivery Mode, Distribution Channel, End User, Patient Age Group - Global Forecast to 2030

  • PDF Icon

    Report

  • 199 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4985893
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Type 1 Diabetes Drug Market grew from USD 19.14 billion in 2024 to USD 20.93 billion in 2025. It is expected to continue growing at a CAGR of 9.09%, reaching USD 32.27 billion by 2030.

Navigating the Future of Type 1 Diabetes Therapeutics

Type 1 diabetes remains one of the most complex and impactful chronic conditions, affecting millions worldwide and demanding continual innovation in therapeutic approaches. Rapid strides in molecular biology have ushered in a new era of insulin analogs and adjunctive therapies, reshaping patient management and clinical outcomes. At the same time, rising healthcare costs and shifting reimbursement paradigms have intensified pressure on stakeholders to optimize efficacy, safety, and affordability.

This study offers a high-level distillation of the key trends and inflection points redefining the Type 1 diabetes drug market. Drawing on rigorous primary interviews with thought leaders, detailed secondary research, and a robust segmentation framework, this executive summary highlights transformative shifts, regulatory influences, and competitive maneuvers that are charting the future of care. By focusing on actionable insights and real-world implications, decision-makers across the value chain-from pharmaceutical innovators and device manufacturers to payers and policy architects-will find a roadmap to anticipate emerging opportunities and navigate uncertainties with confidence.

Disruptive Innovations Reshaping Insulin Therapy Landscape

Over the past several years, the landscape of insulin delivery and glucose management has undergone a fundamental transformation driven by technological breakthroughs and patient-centric innovation. Novel long-acting and ultra-long-acting insulin analogs have extended control windows, while adjunctive therapies targeting immune modulation and beta-cell preservation are advancing through late-stage clinical trials. Concurrently, closed-loop automated insulin delivery systems are transitioning from breakthrough devices to mainstream standards of care, integrating continuous glucose monitoring with intelligent dosing algorithms.

Moreover, the rise of digital health platforms is enabling remote monitoring, predictive analytics, and personalized coaching, fostering greater adherence and glycemic stability. Biosimilar approvals are introducing cost competition, prompting incumbents to refine pricing strategies and bolster patient support programs. Regulators are increasingly receptive to real-world evidence, expediting pathways for therapies that demonstrate meaningful clinical benefit. Altogether, these converging dynamics are redefining therapeutic expectations and elevating patient outcomes.

Assessing the 2025 Tariff Shocks on United States Diabetes Medications

In 2025, the United States implemented a revised tariff regime on imported diabetes drugs and delivery devices, aiming to strengthen domestic manufacturing while offsetting federal budget pressures. This shift has reverberated across the supply chain, generating elevated input costs for distributors and wholesalers that have the dual effect of compressing margins and prompting price adjustments at the point of care. Manufacturers are responding by reconsidering offshore production sites, engaging in strategic sourcing agreements, and exploring vertical integration to mitigate exposure to further trade policy volatility.

At the same time, payers and pharmacy benefit managers are reassessing formulary alignments to accommodate cost increases, potentially accelerating the adoption of biosimilars and non-branded insulins. Patient access programs have become vital in shielding vulnerable populations from sudden price hikes, while advocacy groups are intensifying pressure on policymakers to calibrate tariff levels. This interplay of economic levers and stakeholder strategies underscores the critical importance of agility and foresight in navigating trade-driven disruptions within the Type 1 diabetes ecosystem.

Leveraging Patient and Product Segmentation to Unlock Insights

A granular segmentation approach reveals nuanced opportunities and challenges within the insulin market. The insulin type dimension spans intermediate-acting, long-acting, rapid-acting, short-acting, and ultra-long-acting formulations, each with distinct clinical profiles and patient preferences. Delivery mode analysis highlights the evolving prominence of pens-both disposable and reusable-alongside the growing interest in patch and infusion pumps versus traditional syringe systems delivered via prefilled devices or vial-and-syringe formats. These modalities shape adherence patterns and inform device innovation trajectories.

Equally critical is the distribution channel breakdown, which encompasses hospital pharmacies in both private and public institutions, online platforms ranging from direct-to-patient services to third-party retailers, and brick-and-mortar chain and independent pharmacies. This channel diversity influences time to therapy initiation, patient education, and support program integration. The end user perspective distinguishes clinical settings such as primary care and specialty clinics, home care scenarios involving caregiver or self-administration, and hospital environments differentiated by ownership models. Finally, the patient age group segmentation covers adult populations-spanning middle aged and young adult cohorts-geriatric groups that include elderly and senior individuals, and pediatric segments encompassing adolescents and children. Together, these layers enable a sophisticated understanding of market demand, patient journeys, and product positioning strategies.

Regional Dynamics Driving the Type 1 Diabetes Market

Regional market dynamics reflect distinct regulatory environments, payer structures, and healthcare infrastructures across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, strong reimbursement frameworks and high rates of technology adoption drive rapid uptake of advanced insulin analogs and closed-loop systems, while governmental cost-containment measures exert pressure on pricing models. Stakeholders are forging public-private partnerships to expand access in underserved communities, particularly in regions with significant urban-rural disparities.

Within Europe Middle East & Africa, heterogeneous regulatory pathways and varied economic landscapes create a mosaic of market entry strategies. Western European nations prioritize value-based pricing and real-world evidence, whereas emerging markets in the Middle East and North Africa region focus on improving fundamental access through public health initiatives. Sub-Saharan Africa presents both urgent unmet needs and logistical challenges related to cold-chain distribution and healthcare workforce training. Meanwhile, the Asia-Pacific region exhibits rapid patient population growth, diversifying markets in China, India, Japan, and Southeast Asia that balance domestic manufacturing ambitions with partnerships for technology transfer. Collectively, these regional nuances shape competitive positioning and strategic investment priorities.

Corporate Strategies Shaping Industry Leadership in Diabetes Care

A handful of multinational corporations continue to dominate the Type 1 diabetes sphere through integrated portfolios spanning insulins, delivery devices, and digital solutions. Novo Nordisk maintains leadership with its robust long-acting insulin franchise and deepening pipeline of adjunctive therapies, while Eli Lilly leverages its expertise in rapid-acting analogs and strategic alliances to expand market share. Sanofi’s diversified biopharmaceutical capabilities are complemented by targeted acquisitions designed to enhance its delivery device offerings and data analytics platforms.

Emerging players and biosimilar manufacturers are challenging established players on price and local manufacturing capacity. Strategic collaborations between device innovators and technology firms are proliferating, giving rise to next-generation closed-loop systems and smart pens. At the same time, specialty companies focusing on immune-modulating therapies and beta-cell regeneration are positioning themselves as disruptors poised to transform the treatment paradigm. Together, these corporate strategies underscore a competitive landscape defined by consolidation, convergence, and the pursuit of differentiated value propositions.

Strategic Imperatives for Industry Stakeholders to Thrive

To thrive in an increasingly competitive and regulated environment, industry leaders must prioritize agility and patient-centric innovation. Investing in end-to-end digital ecosystems that integrate continuous glucose monitoring data, predictive algorithms, and telehealth modalities can enhance adherence and outcomes while generating real-world evidence to support pricing negotiations. Strengthening supply chain resilience through diversified sourcing, onshoring key components, and strategic inventory management will mitigate exposure to geopolitical risks and tariff fluctuations.

Engaging payers and policy stakeholders early in the development cycle to co-create value frameworks can accelerate market access and reimbursement decisions. Collaborating with patient advocacy groups to design targeted support programs will deepen trust and improve therapy initiation rates. Finally, fostering open innovation models and cross-sector partnerships-whether with biotech firms exploring novel immunotherapies or technology companies developing advanced delivery mechanisms-will unlock new growth avenues and position organizations at the vanguard of next-generation diabetes care.

Rigorous Research Framework Underpinning Market Analysis

The insights presented in this analysis derive from a comprehensive, multi-phase research approach. Initial desk research involved systematic reviews of peer-reviewed journals, regulatory filings, company financial disclosures, and reputable industry databases. This secondary analysis was complemented by in-depth interviews with endocrinologists, diabetes educators, payers, device engineers, and policy experts to capture diverse perspectives on therapy adoption, patient preferences, and market barriers.

Data triangulation techniques ensured consistency across sources, while an iterative validation process engaged external advisors to challenge assumptions and refine projections. Segmentation frameworks for product type, delivery mode, distribution channel, end user, and patient demographics were applied to structure insights and identify cross-cutting trends. Finally, qualitative findings were synthesized with real-world case studies and scenario analyses to highlight actionable implications. This rigorous methodology underpins the robustness and credibility of the strategic recommendations provided.

Consolidating Insights and Charting Next Steps

The collective findings underscore a dynamic and rapidly evolving Type 1 diabetes landscape characterized by technological breakthroughs, shifting policy levers, and heightened competitive intensity. Transformative insulin analogs and delivery technologies are raising the bar for therapeutic efficacy and patient convenience, while trade policy adjustments and market segmentation complexities demand strategic foresight.

Regional disparities in reimbursement, regulatory requirements, and infrastructure continue to shape differentiated market opportunities. Leading companies are consolidating their positions through targeted acquisitions, alliances, and digital health investments, even as biosimilar entrants and biotech innovators introduce new vectors of competition. Stakeholders that embrace patient-centric models, agile supply chain strategies, and collaborative value creation will be best positioned to capture emerging growth pockets and mitigate downside risks.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Insulin Type
    • Intermediate-Acting
    • Long-Acting
    • Rapid-Acting
    • Short-Acting
    • Ultra-Long-Acting
  • Delivery Mode
    • Pen
      • Disposable Pen
      • Reusable Pen
    • Pump
      • Insulin Pump
      • Patch Pump
    • Syringe
      • Prefilled Syringe
      • Vial And Syringe
  • Distribution Channel
    • Hospital Pharmacy
      • Private Hospitals
      • Public Hospitals
    • Online Pharmacy
      • Direct-To-Patient
      • Third-Party Online Retailers
    • Retail Pharmacy
      • Chain Pharmacy
      • Independent Pharmacy
  • End User
    • Clinics
      • Primary Care Clinics
      • Specialty Clinics
    • Home Care
      • Caregiver Administration
      • Self Administration
    • Hospitals
      • Private Hospitals
      • Public Hospitals
  • Patient Age Group
    • Adult
      • Middle Aged
      • Young Adult
    • Geriatric
      • Elderly
      • Senior
    • Pediatric
      • Adolescent
      • Child
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Novo Nordisk A/S
  • Sanofi S.A.
  • Eli Lilly and Company
  • Biocon Limited
  • Viatris Inc.
  • Wockhardt Limited
  • MannKind Corporation
  • Dr. Reddy’s Laboratories Limited
  • Glenmark Pharmaceuticals Limited
  • Lupin Limited

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Type 1 Diabetes Drug Market, by Insulin Type
8.1. Introduction
8.2. Intermediate-Acting
8.3. Long-Acting
8.4. Rapid-Acting
8.5. Short-Acting
8.6. Ultra-Long-Acting
9. Type 1 Diabetes Drug Market, by Delivery Mode
9.1. Introduction
9.2. Pen
9.2.1. Disposable Pen
9.2.2. Reusable Pen
9.3. Pump
9.3.1. Insulin Pump
9.3.2. Patch Pump
9.4. Syringe
9.4.1. Prefilled Syringe
9.4.2. Vial And Syringe
10. Type 1 Diabetes Drug Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.2.1. Private Hospitals
10.2.2. Public Hospitals
10.3. Online Pharmacy
10.3.1. Direct-To-Patient
10.3.2. Third-Party Online Retailers
10.4. Retail Pharmacy
10.4.1. Chain Pharmacy
10.4.2. Independent Pharmacy
11. Type 1 Diabetes Drug Market, by End User
11.1. Introduction
11.2. Clinics
11.2.1. Primary Care Clinics
11.2.2. Specialty Clinics
11.3. Home Care
11.3.1. Caregiver Administration
11.3.2. Self Administration
11.4. Hospitals
11.4.1. Private Hospitals
11.4.2. Public Hospitals
12. Type 1 Diabetes Drug Market, by Patient Age Group
12.1. Introduction
12.2. Adult
12.2.1. Middle Aged
12.2.2. Young Adult
12.3. Geriatric
12.3.1. Elderly
12.3.2. Senior
12.4. Pediatric
12.4.1. Adolescent
12.4.2. Child
13. Americas Type 1 Diabetes Drug Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Type 1 Diabetes Drug Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Type 1 Diabetes Drug Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Novo Nordisk A/S
16.3.2. Sanofi S.A.
16.3.3. Eli Lilly and Company
16.3.4. Biocon Limited
16.3.5. Viatris Inc.
16.3.6. Wockhardt Limited
16.3.7. MannKind Corporation
16.3.8. Dr. Reddy’s Laboratories Limited
16.3.9. Glenmark Pharmaceuticals Limited
16.3.10. Lupin Limited
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. TYPE 1 DIABETES DRUG MARKET MULTI-CURRENCY
FIGURE 2. TYPE 1 DIABETES DRUG MARKET MULTI-LANGUAGE
FIGURE 3. TYPE 1 DIABETES DRUG MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 16. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. TYPE 1 DIABETES DRUG MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. TYPE 1 DIABETES DRUG MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. TYPE 1 DIABETES DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INTERMEDIATE-ACTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY LONG-ACTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY RAPID-ACTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SHORT-ACTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ULTRA-LONG-ACTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DISPOSABLE PEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY REUSABLE PEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN PUMP, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PATCH PUMP, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY VIAL AND SYRINGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DIRECT-TO-PATIENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY THIRD-PARTY ONLINE RETAILERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PRIMARY CARE CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CAREGIVER ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SELF ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY MIDDLE AGED, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY YOUNG ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ELDERLY, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SENIOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ADOLESCENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CHILD, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 100. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
TABLE 101. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 102. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, 2018-2030 (USD MILLION)
TABLE 103. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, 2018-2030 (USD MILLION)
TABLE 104. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, 2018-2030 (USD MILLION)
TABLE 105. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 107. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 108. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 109. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 110. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 111. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 112. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 113. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 114. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 115. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 116. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 117. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
TABLE 118. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 119. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, 2018-2030 (USD MILLION)
TABLE 120. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, 2018-2030 (USD MILLION)
TABLE 121. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, 2018-2030 (USD MILLION)
TABLE 122. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 123. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 124. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 125. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 126. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 127. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 128. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 129. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 130. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 131. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 132. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 133. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 134. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
TABLE 135. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 136. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, 2018-2030 (USD MILLION)
TABLE 137. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, 2018-2030 (USD MILLION)
TABLE 138. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, 2018-2030 (USD MILLION)
TABLE 139. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 140. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 141. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 142. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 143. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 144. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 145. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 146. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 147. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 148. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 149. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 150. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 151. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
TABLE 152. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 153. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, 2018-2030 (USD MILLION)
TABLE 154. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, 2018-2030 (USD MILLION)
TABLE 155. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, 2018-2030 (USD MILLION)
TABLE 156. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 157. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 158. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 159. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 160. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 161. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 162. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 163. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 164. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 165. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 166. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 167. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, 2018-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, 2018-2030 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, 2018-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 186. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 188. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, 2018-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, 2018-2030 (USD MILLION)
TABLE 190. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, 2018-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 192. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 194. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 196. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 198. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 200. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 201. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 202. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 203. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
TABLE 204. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 205. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, 2018-2030 (USD MILLION)
TABLE 206. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, 2018-2030 (USD MILLION)
TABLE 207. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, 2018-2030 (USD MILLION)
TABLE 208. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 209. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 210. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 211. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 212. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 213. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 214. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 215. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 216. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 217. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 218. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 219. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 220. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
TABLE 221. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 222. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, 2018-2030 (USD MILLION)
TABLE 223. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, 2018-2030 (USD MILLION)
TABLE 224. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, 2018-2030 (USD MILLION)
TABLE 225. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 226. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 227. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 228. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 229. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 230. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 231. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 232. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 233. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 234. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 235. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 236. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 237. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
TABLE 238. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 239. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, 2018-2030 (USD MILLION)
TABLE 240. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, 2018-2030 (USD MILLION)
TABLE 241. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, 2018-2030 (USD MILLION)
TABLE 242. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 243. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 244. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 245. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 246. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 247. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 248. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 249. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 250. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 251. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 252. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 253. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 254. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
TABLE 255. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 256. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, 2018-2030 (USD MILLION)
TABLE 257. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, 2018-2030 (USD MILLION)
TABLE 258. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, 2018-2030 (USD MILLION)
TABLE 259. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 260. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 261. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 262. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 263. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 264. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 265. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 266. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 267. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 268. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 269. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 270. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 271. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
TABLE 272. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 273. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, 2018-2030 (USD MILLION)
TABLE 274. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, 2018-2030 (USD MILLION)
TABLE 275. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, 2018-2030 (USD MILLION)
TABLE 276. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 277. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 278. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 279. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 280. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 281. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 282. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 283. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 284. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 285. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 286. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 287. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 288. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
TABLE 289. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 290. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, 2018-2030 (USD MILLION)
TABLE 291. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, 2018-2030 (USD MILLION)
TABLE 292. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, 2018-2030 (USD MILLION)
TABLE 293. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 294. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 295. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 296. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 297. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 298. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 299. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 300. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 301. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 302. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 303. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 304. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 305. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
TABLE 306. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 307. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, 2018-2030 (USD MILLION)
TABLE 308. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, 2018-2030 (USD MILLION)
TABLE 309. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, 2018-2030 (USD MILLION)
TABLE 310. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 311. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 312. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 313. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 314. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 315. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 316. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 317. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 318. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 319. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 320. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 321. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 322. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
TABLE 323. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 324. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, 2018-2030 (USD MILLION)
TABLE 325. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, 2018-2030 (USD MILLION)
TABLE 326. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, 2018-2030 (USD MILLION)
TABLE 327. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 328. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 329. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 330. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 331. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 332. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 333. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 334. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 335. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 336. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 337. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 338. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 339. DENMARK TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
TABLE 340. DENMARK TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 341. DENMARK TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, 2018-2030 (USD MILLION)
TABLE 342. DENMARK TYPE 1 DIABETES D

Companies Mentioned

The companies profiled in this Type 1 Diabetes Drug market report include:
  • Novo Nordisk A/S
  • Sanofi S.A.
  • Eli Lilly and Company
  • Biocon Limited
  • Viatris Inc.
  • Wockhardt Limited
  • MannKind Corporation
  • Dr. Reddy’s Laboratories Limited
  • Glenmark Pharmaceuticals Limited
  • Lupin Limited

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages199
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 20.93 Billion
Forecasted Market Value ( USD ) by 2030 $ 32.27 Billion
Compound Annual Growth Rate9.0%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Type 1 Diabetes: Epidemiology Forecast to 2033 - Product Image

Type 1 Diabetes: Epidemiology Forecast to 2033

  • Report
  • 69 Pages
  • Global
From
Diabetes Drugs Market by Drug Class, Route Of Administration, Patient Type, Distribution Channel, Treatment Regimen - Global Forecast to 2030 - Product Image

Diabetes Drugs Market by Drug Class, Route Of Administration, Patient Type, Distribution Channel, Treatment Regimen - Global Forecast to 2030

  • Report
  • 199 Pages
  • Global
From
Type 2 Diabetes Drugs Market by Drug Class, Route Of Administration, Treatment Line, Distribution Channel, Brand Type, Patient Age Group, Patient Gender - Global Forecast to 2030 - Product Image

Type 2 Diabetes Drugs Market by Drug Class, Route Of Administration, Treatment Line, Distribution Channel, Brand Type, Patient Age Group, Patient Gender - Global Forecast to 2030

  • Report
  • 193 Pages
  • Global
From
Antidiabetics Market Size, Share & Trends Analysis Report by Drug Class (GLP-1 Receptor Agonists, Insulin), Diabetes Type (Type 1, 2), Route of Administration (Oral, Intravenous), Distribution Channel, Region, with Growth Forecasts, 2025-2030 - Product Image

Antidiabetics Market Size, Share & Trends Analysis Report by Drug Class (GLP-1 Receptor Agonists, Insulin), Diabetes Type (Type 1, 2), Route of Administration (Oral, Intravenous), Distribution Channel, Region, with Growth Forecasts, 2025-2030

  • Report
  • 100 Pages
  • Global
From
SGLT2 Inhibitors Market Size, Share & Trends Analysis Report By Drug (Jardiance, Farxiga, Inpefa, Invokana), By Indication (Diabetes, Cardiovascular), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

SGLT2 Inhibitors Market Size, Share & Trends Analysis Report By Drug (Jardiance, Farxiga, Inpefa, Invokana), By Indication (Diabetes, Cardiovascular), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 159 Pages
  • Global
From

About the Type 1 Diabetes Drug Market

The Type 1 Diabetes Drug market is a subset of the Immune Disorders Drugs market. It is composed of drugs used to treat Type 1 Diabetes, an autoimmune disorder in which the body's immune system attacks the cells that produce insulin. These drugs are used to help regulate blood sugar levels and reduce the risk of complications associated with the disease. Commonly used Type 1 Diabetes Drugs include insulin, sulfonylureas, meglitinides, and GLP-1 agonists. These drugs are typically administered orally or through injection. The Type 1 Diabetes Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and Boehringer Ingelheim. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.